COVID-19 and metabolic disease: Mechanisms and clinical management.
- Steenblock, C.
- Schwarz, P.E.
- Ludwig, B.
- Linkermann, A.
- Zimmet, P.
- Kulebyakin, K.
- Tkachuk, V.A.
- Markov, A.G.
- Lehnert, H.
- Hrabě de Angelis, M.
- Rietzsch, H.
- Rodionov, R.N.
- Khunti, K.
- Hopkins, D.
- Birkenfeld, A.L.
- Boehm, B.
- Holt, R.I.G.
- Skyler, J.S.
- deVries, J.H.
- Renard, E.
- Eckel, R.H.
- Alberti, K.G.M.M.
- Geloneze, B.
- Chan, J.C.
- Mbanya, J.C.
- Onyegbutulem, H.C.
- Ramachandran, A.
- Basit, A.
- Hassanein, M.T.
- Bewick, G.A.
- Spinas, G.A.
- Beuschlein, F.
- Landgraf, R.
- Rubino, F.
- Mingrone, G.
- Bornstein, S.R.
DOIAbstract
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic...
Add to ORKG